{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:24:41Z","timestamp":1773887081980,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009751","name":"University of California Davis School of Veterinary Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007707","name":"University of California, Davis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007707","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005595","name":"University of California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.dmd.2025.100179","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T23:23:19Z","timestamp":1759965799000},"page":"100179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CYP2B6 downregulation by cell-penetrating dominant-negative activating transcription factor 5 peptide in glioblastoma cells"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8607-9816","authenticated-orcid":false,"given":"Ji Yae","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1128-0740","authenticated-orcid":false,"given":"Orli","family":"Algranatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5612-1221","authenticated-orcid":false,"given":"James M.","family":"Angelastro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.dmd.2025.100179_bib1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.gpb.2016.03.008","article-title":"Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine","volume":"14","author":"Ahmed","year":"2016","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"2","key":"10.1016\/j.dmd.2025.100179_bib2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3390\/genes13020311","article-title":"Pharmacogenetics of drugs used in the treatment of cancers","volume":"13","author":"Franczyk","year":"2022","journal-title":"Genes (Basel)"},{"issue":"Suppl 4","key":"10.1016\/j.dmd.2025.100179_bib3","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nou223","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100179_bib4","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/biomedicines9030324","article-title":"Current FDA-approved therapies for high-grade malignant gliomas","volume":"9","author":"Fisher","year":"2021","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.dmd.2025.100179_bib5","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/cncr.20072","article-title":"Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme","volume":"100","author":"Chamberlain","year":"2004","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.dmd.2025.100179_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/nbm.3748","article-title":"Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide","volume":"30","author":"Ferrer-Font","year":"2017","journal-title":"NMR Biomed"},{"issue":"34","key":"10.1016\/j.dmd.2025.100179_bib7","doi-asserted-by":"crossref","first-page":"12873","DOI":"10.1073\/pnas.0605496103","article-title":"Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses","volume":"103","author":"Fulci","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.dmd.2025.100179_bib8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/jat\/26.7.438","article-title":"Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases","volume":"26","author":"Jannetto","year":"2002","journal-title":"J Anal Toxicol"},{"issue":"7","key":"10.1016\/j.dmd.2025.100179_bib9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.trecan.2017.05.004","article-title":"Targeting ATF5 in cancer","volume":"3","author":"Angelastro","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.dmd.2025.100179_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fgene.2013.00024","article-title":"Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance","volume":"4","author":"Zanger","year":"2013","journal-title":"Front Genet"},{"issue":"5","key":"10.1016\/j.dmd.2025.100179_bib11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.apsb.2016.07.016","article-title":"Insights into CYP2B6-mediated drug-drug interactions","volume":"6","author":"Hedrich","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.dmd.2025.100179_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.692234","article-title":"CYP2B6 functional variability in drug metabolism and exposure across populations-implication for drug safety, dosing, and individualized therapy","volume":"12","author":"Langmia","year":"2021","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.dmd.2025.100179_bib13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13568-020-01064-w","article-title":"Synthesis of cyclophosphamide metabolites by a peroxygenase from Marasmius rotula for toxicological studies on human cancer cells","volume":"10","author":"Steinbrecht","year":"2020","journal-title":"AMB Express"},{"issue":"1","key":"10.1016\/j.dmd.2025.100179_bib14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/17425250903483207","article-title":"Efavirenz in the therapy of HIV infection","volume":"6","author":"Rakhmanina","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100179_bib15","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/ALN.0000000000000867","article-title":"Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism","volume":"123","author":"Kharasch","year":"2015","journal-title":"Anesthesiology"},{"issue":"7","key":"10.1016\/j.dmd.2025.100179_bib16","first-page":"917","article-title":"The pharmacology and toxicology of \"ecstasy\" (MDMA) and related drugs","volume":"165","author":"Kalant","year":"2001","journal-title":"CMAJ"},{"issue":"3","key":"10.1016\/j.dmd.2025.100179_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.euroneuro.2017.01.008","article-title":"Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects","volume":"27","author":"Vizeli","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"issue":"48","key":"10.1016\/j.dmd.2025.100179_bib18","doi-asserted-by":"crossref","first-page":"84595","DOI":"10.18632\/oncotarget.21102","article-title":"The transcription factor ATF5: role in cellular differentiation, stress responses, and cancer","volume":"8","author":"Sears","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.dmd.2025.100179_bib19","doi-asserted-by":"crossref","first-page":"581","DOI":"10.3390\/cells12040581","article-title":"Targeting transcription factors ATF5, CEBPB and CEBPD with cell-penetrating peptides to treat brain and other cancers","volume":"12","author":"Greene","year":"2023","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.dmd.2025.100179_bib20","doi-asserted-by":"crossref","first-page":"12718","DOI":"10.18632\/oncotarget.7212","article-title":"Regression\/eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide","volume":"7","author":"Cates","year":"2016","journal-title":"Oncotarget"},{"issue":"18","key":"10.1016\/j.dmd.2025.100179_bib21","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1158\/1078-0432.CCR-15-2827","article-title":"A synthetic cell-penetrating dominant-negative ATF5 peptide exerts anticancer activity against a broad spectrum of treatment-resistant cancers","volume":"22","author":"Karpel-Massler","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.dmd.2025.100179_bib22","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1124\/dmd.107.019380","article-title":"ATF5 is a highly abundant liver-enriched transcription factor that cooperates with constitutive androstane receptor in the transactivation of CYP2B6: implications in hepatic stress responses","volume":"36","author":"Pascual","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2025.100179_bib23","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1523\/JNEUROSCI.23-11-04590.2003","article-title":"Regulated expression of ATF5 is required for the progression of neural progenitor cells to neurons","volume":"23","author":"Angelastro","year":"2003","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.dmd.2025.100179_bib24","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/1541-7786.MCR-19-0631","article-title":"Dominant-negative ATF5 compromises cancer cell survival by targeting CEBPB and CEBPD","volume":"18","author":"Sun","year":"2020","journal-title":"Mol Cancer Res"},{"issue":"3","key":"10.1016\/j.dmd.2025.100179_bib25","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch","year":"2007","journal-title":"Am Fam Physician"},{"issue":"4","key":"10.1016\/j.dmd.2025.100179_bib26","first-page":"263","article-title":"Basic review of the cytochrome P450 system","volume":"4","author":"McDonnell","year":"2013","journal-title":"J Adv Pract Oncol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100179_bib27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver","volume":"11","author":"Lang","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"23","key":"10.1016\/j.dmd.2025.100179_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312808","article-title":"Cytochrome P450 enzymes and drug metabolism in humans","volume":"22","author":"Zhao","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.dmd.2025.100179_bib29","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1021\/acschemneuro.8b00155","article-title":"Dark classics in chemical neuroscience: 3,4-methylenedioxymethamphetamine","volume":"9","author":"Dunlap","year":"2018","journal-title":"ACS Chem Neurosci"},{"issue":"10","key":"10.1016\/j.dmd.2025.100179_bib30","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/dmd.119.086348","article-title":"Efavirenz metabolism: influence of polymorphic CYP2B6 variants and stereochemistry","volume":"47","author":"Wang","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2025.100179_bib31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2174\/1389201018666170207141525","article-title":"Personalized medicine applied to forensic sciences: new advances and perspectives for a tailored forensic approach","volume":"18","author":"Santurro","year":"2017","journal-title":"Curr Pharm Biotechnol"},{"issue":"12","key":"10.1016\/j.dmd.2025.100179_bib32","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/phar.1852","article-title":"Role of cytochrome P450 2B6 pharmacogenomics in determining efavirenz-mediated central nervous system toxicity, treatment outcomes, and dosage adjustments in patients with human immunodeficiency virus infection","volume":"36","author":"Vo","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.dmd.2025.100179_bib33","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"14","key":"10.1016\/j.dmd.2025.100179_bib34","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.3390\/cancers15143567","article-title":"Methadone potentiates the cytotoxicity of temozolomide by impairing calcium homeostasis and dysregulation of PARP in glioblastoma cells","volume":"15","author":"Honc","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.dmd.2025.100179_bib35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3390\/toxics9110292","article-title":"Pharmacogenetics and forensic toxicology: a new step towards a multidisciplinary approach","volume":"9","author":"Di Nunno","year":"2021","journal-title":"Toxics"},{"key":"10.1016\/j.dmd.2025.100179_bib36","first-page":"1","article-title":"Drug overdose deaths in the United States, 1999-2020","volume":"426","author":"Hedegaard","year":"2021","journal-title":"NCHS Data Brief"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625094887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625094887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:42:25Z","timestamp":1773870145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625094887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0090955625094887"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100179","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP2B6 downregulation by cell-penetrating dominant-negative activating transcription factor 5 peptide in glioblastoma cells","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100179"}}